Publications

Authors:

Latagliata, Roberto; Attolico, Immacolata; Monika Trawinska, Malgorzata; Capodanno, Isabella; Annunziata, Mario; Elena, Chiara; Luciano, Luigiana; Crugnola, Monica; Bergamaschi, Micaela; Bonifacio, Massimiliano; Barat(`(e)), Claudia; Mauro, Endri; Binotto, Gianni; Sgherza, Nicola; Aguzzi, Chiara; Monteleone, Barbara; Sor(`(a)), Federica; Caocci, Giovanni; Luzi, Debora; Mariggi(`(o)), Elena; Scaffidi, Luigi; Cattaneo, Daniele; Gozzini, Antonella; Di Veroli, Ambra; Abruzzese, Elisabetta; Galimberti, Sara; Iurlo, Alessandra; Specchia, Giorgina; Breccia, Massimo

Title:

Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors

Year:

2021

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

Hematological Oncology

ISSN of journal:

0278-0232

N° Volume:

39

Number or Folder:

3

Page numbers:

401-408

Keyword:

bosutinib; chronic myeloid leukemia; elderly people; real-life clinical experience; Aged; Aniline Compounds; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinolines; Survival Rate

Short description of contents:

To evaluate the role of bosutinib in elderly patients aged >65 years with chronic myeloid leukemia (CML), a real-life cohort of 101 chronic-phase CML patients followed up in 23 Italian centers and treated with bosutinib in second or a subsequent line was retrospectively evaluated. Starting dose of bosutinib was 500 mg/day in 25 patients (24.8%), 400 mg/day in 7 patients (6.9%), 300 mg/day in 33 patients (32.7%), 200 mg/day in 34 patients (33.6%), and 100 mg/day in 2 patients (2.0%). Grade 3/4 hematological toxicity occurred in 7/101 patients (6.9%) and grade 3/4 extra-hematological toxicity in 19/101 patients (18.8%). Permanent bosutinib discontinuation due to toxicity was needed in 12 patients (11.9%). Among the 96 patients evaluable for response, 74 (77.0%) achieved a complete cytogenetic response (CCyR), while 64 of these 74 patients in CCyR (66.6% of all 96 evaluable patients) also achieved a molecular response (MR) (major MR [MR 3.0] in 21 [21.8%], deep MR [MR 4.0/4.5] in 43 [44.8%]). The 3-year event-free survival and overall survival of the whole patients' cohort from bosutinib start were 60.9% (CI 95% 49.3-72.5) and 86.4% (CI 95% 77.2-95.6), respectively. Our real-life data show that bosutinib is effective, with a favorable safety profile, also in elderly patients with important comorbidities and resistance and/or intolerance to previous tyrosine-kinase inhibitor treatments. As a consequence, it could play a significant role in current clinical practice for frail patients.

Product ID:

122585

Handle IRIS:

11562/1049486

Last Modified:

October 9, 2024

Bibliographic citation:

Latagliata, Roberto; Attolico, Immacolata; Monika Trawinska, Malgorzata; Capodanno, Isabella; Annunziata, Mario; Elena, Chiara; Luciano, Luigiana; Crugnola, Monica; Bergamaschi, Micaela; Bonifacio, Massimiliano; Barat(`(e)), Claudia; Mauro, Endri; Binotto, Gianni; Sgherza, Nicola; Aguzzi, Chiara; Monteleone, Barbara; Sor(`(a)), Federica; Caocci, Giovanni; Luzi, Debora; Mariggi(`(o)), Elena; Scaffidi, Luigi; Cattaneo, Daniele; Gozzini, Antonella; Di Veroli, Ambra; Abruzzese, Elisabetta; Galimberti, Sara; Iurlo, Alessandra; Specchia, Giorgina; Breccia, Massimo, Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors «Hematological Oncology» , vol. 39 , n. 3 , 2021 , pp. 401-408

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo